A Phase 2 interventional study of Cyclosporine 0.010% eye drops and Cyclosporine 0.005% eye drops in Laser In Situ Keratomileusis, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2013-07-11.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the safety and efficacy of Cyclosporine 0.005% and 0.010% eye drops administered twice daily before and following LASIK surgery.
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
First submitted before Allergan became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Drug: Cyclosporine 0.010% eye drops
Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Drug: Cyclosporine 0.005% eye drops
Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Drug: Placebo (Vehicle for Cyclosporine)
Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Time to Cure
Time to cure is defined as the number of days after laser in situ keratomileusis (LASIK) surgery that the patient has corneal sensitivity (the capability of the cornea to respond to stimulation) ≥ 50 millimeters in all 9 regions of both eyes after LASIK surgery. A patient is considered cured at the first of 2 consecutive visits meeting these criteria. The Inter-Quartile Range presented is actually the 25th Quantile and the 75th Quantile obtained from the Kaplan-Meier Model.
Time frame: 6 Months
Time to Worst Outcome Post-LASIK Surgery in Tear Film Assessment
The time to the worst outcome post-LASIK surgery in tear film stability is assessed using the Ocular Scatter Index (OSI). The OSI is calculated by an instrument which takes images of the eye over time. OSI values ≥3.0 indicate lower tear film quality resulting in a loss of visual acuity. The worst outcome post-LASIK surgery is defined as the shortest time to OSI ≥3 across both eyes and post-LASIK surgery months 3 to 6.
Time frame: Months 3 to 6
Percentage of Patients With Cumulative Poor Vision
Cumulative Poor Vision is determined binocularly per patient (using both eyes at the same time) from the Poor Vision question on the Ocular Surface Disease Index (OSDI) questionnaire. Severity of poor vision is graded on a 5-point scale (0 = none of the time, 1 = some of the time, 2 = half of the time, 3 = most of the time, 4 = all of the time). Cumulative poor vision is defined as at least one poor vision score ≥ 1 beginning at Month 3 post-LASIK.
Time frame: Month 3, Month 4, Month 5, Month 6
Worst Outcome Post-LASIK Surgery in Reading Speed Assessment
Reading speed is determined using the MNREAD™ Reading Card. The MNREAD™ reading card is designed to simulate a normal every day reading scenario using binocular vision (both eyes at the same time). The MNREAD™ Reading speed is calculated as (60) X \[Number of words on card - (reading errors)\]/ (number of seconds until the card is read). The worst outcome is defined as the smallest number of words per minute across post-LASIK surgery months 3 to 6.
Time frame: Months 3 to 6
| Milestone | Cyclosporine 0.010% Eye Drops | Cyclosporine 0.005% Eye Drops | Placebo (Vehicle for Cyclosporine) |
|---|---|---|---|
| Started | 207 | 209 | 205 |
| Completed | 187 | 181 | 180 |
| Not completed | 20 | 28 | 25 |
Time to cure is defined as the number of days after laser in situ keratomileusis (LASIK) surgery that the patient has corneal sensitivity (the capability of the cornea to respond to stimulation) ≥ 50 millimeters in all 9 regions of both eyes after LASIK surgery. A patient is considered cured at the first of 2 consecutive visits meeting these criteria. The Inter-Quartile Range presented is actually the 25th Quantile and the 75th Quantile obtained from the Kaplan-Meier Model.
| Days | Cyclosporine 0.010% Eye Drops | Cyclosporine 0.005% Eye Drops | Placebo (Vehicle for Cyclosporine) |
|---|---|---|---|
| Time to Cure | 189.0 (181.0 to NA) | 194.0 (181.0 to 196.0) | 189.0 (180.0 to NA) |
The time to the worst outcome post-LASIK surgery in tear film stability is assessed using the Ocular Scatter Index (OSI). The OSI is calculated by an instrument which takes images of the eye over time. OSI values ≥3.0 indicate lower tear film quality resulting in a loss of visual acuity. The worst outcome post-LASIK surgery is defined as the shortest time to OSI ≥3 across both eyes and post-LASIK surgery months 3 to 6.
| Seconds | Cyclosporine 0.010% Eye Drops | Cyclosporine 0.005% Eye Drops | Placebo (Vehicle for Cyclosporine) |
|---|---|---|---|
| Time to Worst Outcome Post-LASIK Surgery in Tear Film Assessment | 11.2 ± 4.24 | 12.0 ± 4.51 | 11.5 ± 4.39 |
Cumulative Poor Vision is determined binocularly per patient (using both eyes at the same time) from the Poor Vision question on the Ocular Surface Disease Index (OSDI) questionnaire. Severity of poor vision is graded on a 5-point scale (0 = none of the time, 1 = some of the time, 2 = half of the time, 3 = most of the time, 4 = all of the time). Cumulative poor vision is defined as at least one poor vision score ≥ 1 beginning at Month 3 post-LASIK.
| Percentage of Patients | Cyclosporine 0.010% Eye Drops | Cyclosporine 0.005% Eye Drops | Placebo (Vehicle for Cyclosporine) |
|---|---|---|---|
| Month 3 | 15.0 | 18.7 | 19.0 |
| Month 4 | 17.9 | 22.5 | 23.9 |
| Month 5 | 21.7 | 26.3 | 24.9 |
| Month 6 | 23.7 | 26.8 | 26.3 |
Reading speed is determined using the MNREAD™ Reading Card. The MNREAD™ reading card is designed to simulate a normal every day reading scenario using binocular vision (both eyes at the same time). The MNREAD™ Reading speed is calculated as (60) X \[Number of words on card - (reading errors)\]/ (number of seconds until the card is read). The worst outcome is defined as the smallest number of words per minute across post-LASIK surgery months 3 to 6.
| Words Per Minute (WPM) | Cyclosporine 0.010% Eye Drops | Cyclosporine 0.005% Eye Drops | Placebo (Vehicle for Cyclosporine) |
|---|---|---|---|
| Worst Outcome Post-LASIK Surgery in Reading Speed Assessment | 173.0 ± 40.17 | 173.7 ± 42.18 | 167.4 ± 45.21 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cyclosporine 0.010% Eye Drops | — | 2/207 (1%) | 78/207 (37.7%) |
| Cyclosporine 0.005% Eye Drops | — | 0/209 (0%) | 66/209 (31.6%) |
| Placebo (Vehicle for Cyclosporine) | — | 3/205 (1.5%) | 66/205 (32.2%) |
| Event | Cyclosporine 0.010% Eye Drops | Cyclosporine 0.005% Eye Drops | Placebo (Vehicle for Cyclosporine) |
|---|---|---|---|
| Abortion SpontaneousPregnancy, puerperium and perinatal conditions | 0/115 | 0/118 | 1/105 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/115 | 0/118 | 1/105 |
| Haemorrhagic Ovarian CystReproductive system and breast disorders | 1/115 | 0/118 | 0/105 |
| Refraction DisorderEye disorders | 0/207 | 0/209 | 1/205 |
| Clavicle FractureInjury, poisoning and procedural complications | 1/207 | 0/209 | 0/205 |
| Event | Cyclosporine 0.010% Eye Drops | Cyclosporine 0.005% Eye Drops | Placebo (Vehicle for Cyclosporine) |
|---|---|---|---|
| Dry EyeEye disorders | 52/207 | 48/209 | 47/205 |
| Punctate KeratitisEye disorders | 13/207 | 11/209 | 10/205 |
| Vision BlurredEye disorders | 13/207 | 7/209 | 9/205 |
| Age, Customized(Participants) | Cyclosporine 0.010% Eye Drops | Cyclosporine 0.005% Eye Drops | Placebo (Vehicle for Cyclosporine) | Total |
|---|---|---|---|---|
| <30 years | 68 | 69 | 77 | 214 |
| 30 to 40 years | 110 | 97 | 92 | 299 |
| >40 years | 29 | 43 | 36 | 108 |
| Sex: Female, Male(Participants) | Cyclosporine 0.010% Eye Drops | Cyclosporine 0.005% Eye Drops | Placebo (Vehicle for Cyclosporine) | Total |
|---|---|---|---|---|
| Female | 115 | 118 | 105 | 338 |
| Male | 92 | 91 | 100 | 283 |
The record gives a start of Oct 2009, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 2 years 3 months after primary completion. A results delay was requested in Apr 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine